Clinical Trial Update: Efficacy and Safety of Insulin Aspart Versus Glibenclamide in Type 2 Diabetes [Phase 3]

View source ↗

Summary

Phase 3 trial comparing insulin aspart to glibenclamide in type 2 diabetes has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Glibenclamide (glibenclamide)
• Insulin aspart (insulin aspart)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | Status: TERMINATED